TrialBritish journal of cancer2015

Assessing the benefit-risk of new treatments using generalised pairwise comparisons: the case of erlotinib in pancreatic cancer.

J Péron et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.